0 313

Cited 0 times in

클로피도그렐 치료에서 CYP2C19 유전자 다형성에 따른 흡연과 뇌졸중 재발 관련성

DC FieldValueLanguage
dc.contributor.author남효석-
dc.contributor.author이경열-
dc.date.accessioned2019-05-29T05:18:20Z-
dc.date.available2019-05-29T05:18:20Z-
dc.date.issued2018-
dc.identifier.issn2508-626X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/169519-
dc.description.abstractBackground:To perform a subgroup analysis of the MAESTRO trial to explore the relationship between smoking status with regard to Cytochrome P450 2C19 (CYP2C19) polymorphisms and stroke recurrence in patients who underwent clopidogrel treatment. Methods:Male patients who underwent VerifyNow assay and CYP2C19 genotyping were selected from the MAESTRO study. CYP2C19 ultrarapid metabolizer or extensive metabolizer and intermediate/unknown metabolizer or poor metabolizer was allocated into the good genotype and poor genotype groups, respectively. Results:Of 393 patients who underwent clopidogrel treatment in the MAESTRO trial, 182 (46.3%) male patients were chosen for this study. The median follow-up duration was 3.0 years (range, 0-4.5). Ninety-five patients (52%) were current smokers. Seventy (38.5%) patients had a good genotype for clopidogrel metabolism and 112 (61.5%) had a poor genotype. Seven (3.8%) patients had a recurrent ischemic stroke. Though there was no significant difference, a trend toward lower recurrent stroke and a major vascular event was observed in the good genotype group among current smokers. The risk of recurrent stroke was 0% and 8.5% in the good genotype and poor genotype groups, respectively (P=0.086). The risk of a major vascular event was 0% and 10.2% in the good genotype and poor genotype groups (P=0.051). In the nonsmokers, there was no reduction in risk for recurrent stroke (0% vs 3.8%, P=0.368) and a major vascular event (2.9% vs 3.8%, P=0.663) in the good genotype group. Conclusions: Smoking status may modify the effect of clopidogrel treatment on outcome according to CYP2C19 polymorphisms.-
dc.description.statementOfResponsibilityprohibition-
dc.languageKorean-
dc.publisher부산·울산·경남 뇌졸중학회-
dc.relation.isPartOfJournal of Vascular Neurology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title클로피도그렐 치료에서 CYP2C19 유전자 다형성에 따른 흡연과 뇌졸중 재발 관련성-
dc.title.alternativeSmoking influence on the effect of clopidogrel in secondary stroke prevention may be dependent on CYP2C19 Polymorphisms-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학교실)-
dc.contributor.googleauthor한상원-
dc.contributor.googleauthor김용재-
dc.contributor.googleauthor서우근-
dc.contributor.googleauthor유성욱-
dc.contributor.googleauthor남효석-
dc.contributor.googleauthor윤성상-
dc.contributor.googleauthor김서현-
dc.contributor.googleauthor이종윤-
dc.contributor.googleauthor이준홍-
dc.contributor.googleauthor황양하-
dc.contributor.googleauthor이준-
dc.contributor.googleauthor이경아-
dc.contributor.googleauthor이경-
dc.contributor.localIdA01273-
dc.contributor.localIdA02648-
dc.contributor.localIdA02648-
dc.relation.journalcodeJ03607-
dc.subject.keywordclopidogrel-
dc.subject.keywordcytochrome-
dc.subject.keywordpolymorphisms-
dc.subject.keywordsmoking-
dc.subject.keywordstroke-
dc.contributor.alternativeNameNam, Hyo Suk-
dc.contributor.affiliatedAuthor남효석-
dc.contributor.affiliatedAuthor이경열-
dc.contributor.affiliatedAuthor이경열-
dc.citation.volume3-
dc.citation.number1-
dc.citation.startPage11-
dc.citation.endPage15-
dc.identifier.bibliographicCitationJournal of Vascular Neurology, Vol.3(1) : 11-15, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.